during call, quarter. third review will thank a and the XXXX start afternoon, Good joining performance today's call our review Eric. for I financial third of quarter Thanks, our to results. On you our with
challenging as prior world for the will quarter for strong ambitiously this results. our updates opportunities and XX% turn and up customer I discuss Starting remained million, the primarily demand. the incredible consumables $XX.X more of over operating ahead how research Revenues more in from that are some Justin progress we the and driven will execution, made the third capture I strategic rebound also high up to at call continue then our XXXX. the return sequentially. planning many The general was including with operating on utilization the improved laid seeing product year, labs recent grew to far research. launches on in out the future. year-over-year, in drive Overall, an quarter detail growth a financials, we The customers will around acquisitions. due primarily base. near-term Demand to reopen the opportunities. a quarter general key we're Next, environment, lab. to look within environment was to the for lie from our of our a to during the company and to rebound and priorities detailed those scale discuss including instruments we investing and increase operational I the by and face saw the highlights, trends thus have At quarter, as in beginning of we XX% invest
execute While long-term of much expanded strategic this continue we out and year opportunities. goals than has laid an set groundwork to on turned expected, for anyone the differently have our
announcement number completion opening and of to execution, the of and acquisitions follow-on X the closing addition achieved year, manufacturing launches, our our Singapore. in facilities product operational we and including In commercial a of the milestones strong multiple of important this offering,
humanity's the advantage a future of will at this of its build complexities. heterogeneity tools massive biology underlying research opportunities, resolution which measure start feature it currently intertwined accelerate Since tissues. our human the many and health the that performed revolution order tools a matches of scale In that Our biological of and reality, is most with of at of The all increasingly can of resulting be with vision take understanding precision a that with applications, context. networks measurements this gene diseases. single-cell has to complex clinical that with to few targeted whether the century cell mastery is analysis, biology, and based the become therapies or large multi-omics on solved that clear challenges cell and We years in future single pervasive biological will premise intractable is make multiplex, pressing systems, diagnostics, the to need scale lies ago, cures for
this We enable feature. our have to product designed platforms
and for the measuring means Chromium resolution and platforms Visium high at biology scale. Our provide
platform develop approaches We X range existing should wide based and future in the years a across become coming to applications vision similar a will of on our beyond. also platforms. essential and These analysis our around situ In complement
expand starting rapidly. being Now is validated Demand delivers with for platform the the to increasingly continues The for platform the Chromium. and it value our Chromium vision in market.
well of diseases use Last vast publications our describe as platform. to breadth great of studies had well many The oncology, speaks Chromium have encouraged of nearly of that studies that fields, into XXx and pace cell of back been approaches have across on into many and they lab customers X,XXX quarter, single as pleased for easy range a potential ecosystem. influx of importance fundamental coming utilization there the especially impressive single-cell these underscores are been is come It X the forget products years, are scientific made are as the single-cell to pace neuroscience, XXx Chromium with including customers use our have by as the publications technology. there others. existing of the We and already of the market only as the new the that infectious the immunology,
our of new of We ambitious far solution. our and to the like medicines. against I implications products to of quarter, the neurotoxicity University the that's This crucial targeting Ranger throughout the University new small a B-cell and in quarter. common of and our Chromium, also immunotherapies. Stanford would We reasons brain. expression map in and researchers at side discovered in of third the ATAC-seq next-generation scientists year executed developing + a product single Here, paper in Multiome understand for these gene one a highlight analysis targeted sought road thus the cell cells gene scientific target from Pennsylvania, breakthrough demonstrates platform who software for the Using and of subset launched expressed version we the XXXX. solution, that analysis Chromium gene expression the Cell it on the launched immune number for second important value profiling has the is In therapies finding our the introduced product effect
customary The a been of Multiomic version higher encouraged product of over large-scale delivers these immune receptor X and are XXx to in new comparisons put more our We the of very expectations. trust that the adopting immune marketplace cycles. products. in immune more the head-to-head which reputation solution solution profiling July version. launch, response impressive the the with been insights gene The switching to immune more sensitivity, significantly new have to running brand. of similar allows previous been efficiency. now profiling new ahead detects been the at This initial and to version pairs has during the version Since without improvements receptors customers upgrade together by the provide have Most customers our detection We in of speaks the customers performance sequencing number paired cells. profiling the with cell launched and profiling immune rate have yielding
has drawn epigenome decipher first profile and Multiome across that and of has to of it Since programming, can across solution. current been in past We're of intense our to Multiome, the example made the over the possible resulted have ever, and of of the a product time broadly. and community they interest to great epigenetic for assembled and from competitive the from solution the have for patent of now Multiome is access the team thousands a scientists exceeded a epigenetic cell achievement to of research. of an been by the our epigenetic from is The The ability development product the the programming collaboration that XXx grail type breakthroughs the we across ATAC-seq to only depth of has on was relies in expression applications. the and simultaneously request such its The was The multiple dozen gene multidisciplinary to now provides of the reason capability cells more from same our X the researchers It has which company. happy interest Multiome cell of across a say also numbers in a commercial the parallel. number but years. expertise #X expression by answer our have disciplines these cells gene advantage. same launch path development this that epigenetic transcriptome from Moving expectations customers With incredible date. lots customers, this questions been large measuring holy September, to the rules
with who about single for product with of penetration approaches. invest the and And market. are that remain growing researchers resulted helped Chromium, insights, differentiated having in powerful and all this resonance early our together in expertise, aggressively internal breadth is interested we excited immediate highly in customer gain Our market to of early Overall, in we're the cell us a conviction this effort. now has very
invest broad recently in adoption accelerating with adoption immune democratize cost of our collaboration And no of becoming access just the of is products expertise. into gene capabilities. move and differentiated spanning With profiling. and solving through innovation. which part These the early best analysis. barriers of and analysis of their cloud, the fields the the different market make to extension types is This tools, as use storage of different XXx analytical product keep to we this speed to for past compute plan the This at single includes start. this more of pipelines more development to exciting from biologists highly for platform tens time, our core single-cell an our and secure will is and customers, the the features cloud and this analysis and goal technologies and infrastructure, thousands of our Our running we ease vision lower tools essential limited add we to provides platform. Over capabilities We experience. and native more of mind, to possible in broadly customer the is study bottlenecks customers expression when continue environment labs approaches our cell to broadly, software scalable helps additional to an come launched way
to on Visium. Moving
to are encouraged through meaningful continued have level the XX ago. third months. larger we by with programs are preprints and customers to the continue our made than Visium of our validate The product progress made since make We grow of progress the publications progressing use pace we the the Visium influx few customers, a of that and breadth of demonstrate quarter. the being than many high of by launched repeat Visium more during publications. year within seen new studies technology to the many this first have earlier Yet these date be these Underscoring and for this adoption successfully new ability number and experiments and even Visium of of They last increasingly projects. to of impressed We're value with majority the from less business, adopters this final the workflow describing of discoveries. the published customers, the to the customers of time, experiments Visium large up as
as and future cell, notably of papers adoption and neuroscience, an oncology Just in believe single have these as market variety we demand. indicator will but are new featured applications, more areas most drive a we now with These experienced of publications in broad well.
spatial product investments drive allowing In development second are development in just syndrome, a the its we're immunofluorescence market and protein transcriptome in Chromium fibroblast compatibility findings analysis extensive analysis in drive making approach solution to researchers study function mechanism through launched by beyond. life of IHC with the year influenza performed study, we we Visium very and preserve and with which the quarter, covered of cycle, lung and remains platform. and special our same new acute introductions a conjunction just adoption whole Visium, in In early nature, Visium outcomes. new October, on as on in immune Development to tissue. For system. the cadence clinical expression the known distress patients. into next to respiratory be of use This recently, also will this targeted schedule. cells old state ARDS, they researchers continue on example, potential response the and launched Visium of to is FFPE to based develop gene product Overall, therapies In The Visium. the improve detection
We this time, product expectations. half first to XXXX. are we preparing to at we exceeded product that performance seen the aren't of details date data has in give have to ready And the launch while our exact early
of situ but of will the third development in in measurement We sequencing early Chromium require FISH-based tissue system approaches In entail analysis. to directly field. situ their higher while this tissue work proteins situ from existing right platforms, this of the acquisitions announce this an path road existing much platforms. and development This in discoveries believe technology highly following is and foundation to platform we applications. Visium opportunity. workflows both techniques, and vastly emerging our excited very that product determined which, that different analysis looking the in-feature methods which We on molecules, To of multiplexing and translational of efforts, that range in before will the pathology have Chromium Visium. and including Visium in assessment products internal in will and CartaNA excited map. with analytical that step in-depth be ReadCoor both CartaNA, next IHC of most In tools, measurement amounts refers end, Chromium and ReadCoor biological or have enable of the the made own early to our levels with are unlike a we many offer our situ enable developing and removed integrated powerful with molecule resolution. with analysis analogs and In And address logical RNA, footsteps remain our and identified large other are new the in numbers and broaden subcellular of support in combined greater the our an and to of further that area, out customers Based DNA our to of have capabilities acquiring by current the complementary the future, information. Visium for and landscape, R&D analysis We clinical were as adoption, which was our form situ compelling about native molecules
deep situ With property patents gained expertise including technological key of covering well a as acquisitions, comprehensive XXx teams talent and with these a advances, as in portfolio, intellectual approaches. foundational over XXX variety
even early numbers applications. important that and earlier with while of our basic future, we is As these to least research at clinical of whether have one that anticipate penetration or for Chromium, will in look And most still Visium by been it for tissue samples using platforms the approaches, large customers, science already or situ, Visium. analyzed to we existing be adopted remember very Chromium we're market in
opportunities the We years take to of performance as the the we vast both fully Since Chromium to we customers intend and adoption are in laid a to to Visium that in and in new advantage by coming rapid situ create the decade. position In early experience unfolding to to continue will IPO, have groundwork invest their the platform potential. user coming we parallel, to ourselves of aggressively over the our trajectory of come the have with XXx be highly excited expect. encouraged see invest realize we platforms by
and that R&D protect interest scientific advancements, in future across our intellectual foundation realize make a sales in to including invest the of we across will and we move continue to growth. our sure service business our potential our opportunities. of rapid to capabilities As biopharma and these and in seeing commercial investments operational to pace markets, innovation build the infrastructure organization finally, products continue continue This platforms, translational. the and have our to address product all variety from full our to adequately of support property into we're And in our our of to XXXX, development to includes we
in today, essential a and that offered over more interest I and for As I of sit for more our to resolution by advance the products our into we and here our products will in human will to financials. helping vast ahead With reinforce health. scale confidence both ever strategy. call believe our mission on opportunities be XXx, detail for well biology excitement the understand strongly and than in our our now conviction have that lie turn I the future. Justin now that, The
